MIT Technology Review6d
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
HIV Drug Makers Get Spooked by Possible Trump Cut, but Impact Looks Manageable
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Yearly HIV prevention injection shows promise in clinical trial
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
Fierce Healthcare1d
HHS may cut HIV prevention efforts at the CDC. Advocates fear changes will spike infections
The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...
STAT1d
Pharmalittle: We’re reading about possible HIV prevention cuts, FDA warning an Africa drugmaker, and more
The U.S. Health and Human Services Department is weighing plans to drastically cut federal government funding for domestic ...
BioSpace1d
Trump Eyes Steep Cuts to CDC HIV Prevention Program
The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...
Study examines a novel way to bring addiction care and HIV prevention to people who inject drugs
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...